<DOC>
	<DOCNO>NCT00476463</DOCNO>
	<brief_summary>Combination therapy anti-HBV activity may increase HBV suppression rate reduce emergence resistant strain . Several new therapeutic agent currently development , however combination therapy trial HBV-infected population recently commence . No trial undertake HIV/HBV co-infected population .</brief_summary>
	<brief_title>Efficacy Tenofovir Emtricitabine ARV-naive Patients With HIV/HBV Co-infection</brief_title>
	<detailed_description>The primary study objective compare HBV DNA suppression level limit detection ( &lt; 400 copies/ml ) week 48 treatment group . Virological clinical anti-HBV efficacy tenofovir emtricitabine antiretroviral naive patient HIV/HBV co-infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Written inform consent Documented HIV infection ( positive serology HIV1 detectable HIV1 RNA ) Age 18 70 year HBV DNA &gt; 106 copies/ml HBsAg positive &gt; 6 month In case document duration HBsAg seropositive le 6 month ( situation likely occur patient newly present HIVoutpatient clinic ) patient eligible patient : 1 . HBsAg positive 2 . HBc core IgM antibody negative 3. liver biopsy give evidence chronic active hepatitis . Thus make likely patient acquire HBV infection 6 month ago . ALT &lt; 10 x ULN Creatinine &lt; = 2.0mg/dl Platelet count &gt; = 50,000/mm3 HIV1 therapy naive No prior exposure antiHBV agent ( LAM , adefovir , TDF ) although prior IFN treatment allow HCVRNA positive AntiHAV IgM positive Acute hepatitis ( serum ALT &gt; 1000 U/L ) Prior LAM , TDF , ADV therapy Active opportunistic infection Other cause chronic liver disease identify ( autoimmune hepatitis , haemochromatosis , Wilsons disease , alfa1antitrypsin deficiency ) Concurrent malignancy require cytotoxic chemotherapy Decompensated Child 's C cirrhosis Alfafetoprotein ( AFP ) &gt; 3X ULN ( unless negative CT scan MRI within 3 month entry date ) Pregnancy lactation Any condition opinion investigator might interfere compliance outcome study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>TDF+FTC</keyword>
	<keyword>FTC</keyword>
	<keyword>HIV/HBV</keyword>
	<keyword>TDF compare TDF+FTC HIV/HBV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>